Retatrutide-ECHEMI

  Product Detail  

1. 1. Core Basic Information

   • Generic Name: Retatrutide
   • Research Code: LY-3437943
   • CAS Number: 1533484-63-7
   • Developer: Eli Lilly and Company
   • Molecular Type: Long-acting synthetic triple agonist peptide modified with C20 fatty diacid side chain
   • Regulatory Status: Late-stage Phase 3 investigational compound, no global marketing approval yet; only accessible via authorized clinical trial programs as of 2026

   2. Chemical & Pharmacokinetic Profile

   Retatrutide is a 39-amino-acid engineered peptide with a lipidated side chain at the 17th lysine residue. The long fatty acid moiety enables reversible binding to circulating serum albumin, extending its systemic half-life to approximately 6 days, supporting once-weekly therapeutic cycles.
   • Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
   • Molecular Weight: 4731.33 Da
   • Steady-state plasma concentration can be achieved within 4–5 weeks of consistent weekly use
   • Linear systemic exposure across the full therapeutic dose range from 2 mg to 12 mg weekly

   3. Mechanism of Action

   Retatrutide acts as a single-molecule triple agonist that simultaneously activates three key metabolic receptors: GLP‑1 receptor, GIP receptor and glucagon receptor, delivering synergistic metabolic regulation unmatched by dual or single-target incretin agents.
   1. GLP‑1 & GIP pathway effects: Stimulate glucose-dependent insulin secretion, suppress inappropriate glucagon release, slow gastric emptying, and activate central satiety signals to reduce caloric intake; lower fasting and postprandial blood glucose steadily.
   2. Glucagon receptor activation: Boost whole-body energy expenditure, selectively break down adipose tissue while preserving lean muscle mass, and improve hepatic lipid metabolism.
   3. Combined triple-pathway activity delivers stronger glycemic control and more profound fat mass reduction compared with GLP‑1/GIP dual agonists.

   4. Investigational Clinical Indications

   All indications are currently under Phase 3 clinical evaluation across global TRIUMPH and TRANSCEND trial programs:
   1. Type 2 diabetes mellitus: Improve long-term glycemic management for adult patients with inadequate blood glucose control via diet and physical activity
   2. Chronic weight management: For adults with obesity or overweight accompanied by comorbidities including hypertension, dyslipidemia and type 2 diabetes
   3. Secondary therapeutic targets: Moderate-severe obstructive sleep apnea, knee osteoarthritis pain, metabolic dysfunction-associated steatotic liver disease (MASLD), chronic low back pain, cardiovascular and renal outcome protection

   5. Standard Dosing Regimen (Clinical Trial Protocol)

   A gradual dose escalation schedule is applied to optimize gastrointestinal tolerability, with fixed weekly administration cycles:
   1. Initial tolerability phase (Weeks 1–4): 2 mg per week
   2. Mid escalation phase (Weeks 5–8): 4 mg per week
   3. Standard maintenance dose (Week 9 onward): 8 mg per week
   4. Max efficacy dose (optional for eligible patients after long-term stable tolerance): Up to 12 mg per week
   • Flexible scheduling: The weekly administration window can be adjusted, with a minimum 4-day gap between two dosing cycles
   • Dose holding rule: If moderate gastrointestinal discomfort persists, maintain the current dose level for an extended period before further escalation

   6. Clinical Efficacy Highlights

   Glycemic Control

   In dedicated T2D trials, retatrutide reduced average HbA1c by 1.7%–1.9% over 40 weeks, with a large proportion of participants reaching individualized glycemic targets. Fasting glucose and postprandial glucose levels remain consistently lowered throughout each weekly cycle.

   Weight Reduction & Body Composition

   Dose-dependent total body mass loss is observed across all trial cohorts:
   • Average 24.2% total weight reduction at the highest tested dose after 48 weeks
   • Up to 28.7% average weight loss after 68 weeks of continuous therapy
   • Predominant loss of visceral and subcutaneous fat; minimal loss of skeletal muscle tissue, bringing superior body composition improvement versus single GLP‑1 agonists

   Additional Metabolic Benefits

   Marked improvements in lipid profiles, liver fat content, sleep apnea symptoms and joint pain linked to excess body weight are documented in secondary trial endpoints.

   7. Safety & Tolerability Profile

   Most Common Mild to Moderate Adverse Reactions (dose-correlated)

   Transient gastrointestinal discomfort including nausea, loose stools, constipation and decreased appetite; these symptoms generally fade within the initial dose titration phase. Other frequent mild responses include fatigue and mild dizziness.

   Important Clinical Warnings & Contraindications

   1. Contraindicated for individuals with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
   2. Not recommended during pregnancy and breastfeeding; discontinue treatment at least 3 months before planned conception
   3. Discontinue use and seek urgent medical care upon persistent severe abdominal pain, which may signal pancreatitis risk
   4. Increased risk of gallbladder-related events may occur alongside rapid weight loss; routine clinical assessment is advised if gallbladder discomfort arises
   5. Use with caution in patients with severe gastrointestinal disorders, history of pancreatitis, or moderate-to-severe renal impairment
   6. Co-administration with insulin or sulfonylurea anti-diabetic agents may raise hypoglycemia risk; dose adjustment of concurrent glucose-lowering medicines may be required

   8. Core Competitive Advantages

   1. First-in-class triple metabolic receptor agonist, combining GLP‑1, GIP and glucagon pathway regulation in one single peptide molecule
   2. Superior weight-lowering potency versus all currently marketed single or dual-target incretin therapies
   3. Once-weekly treatment cycle reduces regular dosing burden and improves long-term treatment persistence
   4. Optimized lipidated peptide structure delivers stable round-the-clock metabolic coverage for the full weekly interval
   5. Broad pipeline development covering diabetes, weight management, liver disease and musculoskeletal comorbidities, offering multi-system metabolic benefits
   6. Preserves lean muscle mass during weight loss via targeted glucagon receptor activation, avoiding excessive muscle wasting seen with some alternative weight-control agents